ROIV
NASD Roivant Sciences Ltd.$35.50 ↑ +0.00 (+0.00%) Trading Up from the previous close of $35.50, $1.29 below the day’s high of $36.79
- YTD change
- +63.59%
- vs 20-day SMA
- -7.12%
- vs 200-day SMA
- +18.17%
Price ranges
Price & Performance
+7.17 (+25.31%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 16.5% away from all-time highs of $42.50
- ROIV is up 64% since the beginning of the year
- ROIV is up 125% over the past 12 months
- ROIV is up 3% over the past 1 month
- 7% of all ROIV investors are betting against ROIV
ROIV reads not so good: price sits above one of the two key moving averages, the 12-month move is +122.2%.
- Previous minute
- +$0.00
- Last hour
- -$0.51
- Last 5 days
- -3.59%
- vs 8-day SMA
- -4.06%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.